Amuvatinib

Drug Profile

Amuvatinib

Alternative Names: HPK-56; MP-470

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Montigen
  • Developer Astex Pharmaceuticals
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c-kit inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Glioblastoma; Small cell lung cancer

Most Recent Events

  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 21 Sep 2012 Efficacy data from the phase II ESCAPE trial in Small cell lung cancer released by Astex Pharmaceuticals
  • 21 Sep 2012 Amuvatinib is available for licensing as of 21 Sep 2012. http://www.astx.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top